European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

A breakthrough laser-based medical device to eradicate bacterial biofilm in chronic wounds and accelerate wound healing.

Descrizione del progetto

Un dispositivo laser sicuro uccide i biofilm batterici nelle ferite croniche

Non esistono al momento metodi per debellare i biofilm batterici che si formano nelle ferite croniche, impedendo una guarigione più rapida per circa 10 milioni di persone in Europa e 6,4 milioni negli Stati Uniti. Il progetto LASER-HEAL affronta questa carenza attraverso un dispositivo che raggiunge le ferite in profondità, caratterizzato da un software che riconosce il letto della ferita e aiuta a posizionare il laser in modo accurato. Questa tecnologia non invasiva utilizza una dozzina di trattamenti di mezz’ora a 1 000 euro per trattamento e non distrugge le cellule della pelle. L’obiettivo prevede innanzitutto la costruzione di una clientela attraverso le cliniche statunitensi, prima di espandersi in Europa e nel mondo.

Obiettivo

Chronic wounds affect 10M in Europe and 6.4 million people in the US, with annual costs of >€72Bn in Europe and >€22 Bn in the US. It is a silent epidemic. Key to this problem is the lack of truly effective solutions that fully eradicate bacteria-protecting biofilms deep within chronic wounds.

We have a game-changing new solution to tackle this problem: LASER-HEAL. LASER-HEAL is a medical device that consists of 1) a laser-generating unit that can reach deep within wounds; 2) optomechatronics to move the laser in a controlled manner and 3) software to recognize the contours and depth of wounds. LASER-HEAL enables, for the first time, non-invasive, safe, low-cost (€1.000 p/treatment), rapid (30 mins/session, total ~12) treatment, compatible with standard of care. We have preliminary data showing killing of all relevant species of bacteria, while human skin cells are left intact.

We will bring LASER-HEAL to the global wound care management market (€29bn in 2017 expected to reach €39bn by 2024). We will respond to the need of this market by delivering an effective antibiofilm device for chronic wounds. We will commercialize LASER-HEAL through sales to US clinics first, through fast FDA approval and confirm willingness to pay. By 2025, we will demonstrate revenue potential for LASER-HEAL, and seek a commercial exit, through acquisition (preferred) by a major medical device company, who will then bring LASER-HEAL to the European and global markets. Cumulative income of €75 million is predicted for LASER-HEAL by 2025 during this phase.

We have a unique proposition, backed by preliminary results and the interest of a major wound care company (confidential for this abstract). We want to undertake a detailed study to map successful market introduction for LASER-HEAL. Funding from SMEi Phase can support us with obtaining crucial market, regulatory and de-risked development informa

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SMEInst-2018-2020-1

Meccanismo di finanziamento

SME-1 - SME instrument phase 1

Coordinatore

VULCUR MEDTECH
Contribution nette de l'UE
€ 50 000,00
Indirizzo
SONDERVIGVEJ 50
VANLOSE
Danimarca

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Danmark Hovedstaden Byen København
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 71 429,00